✦ LIBER ✦

Efficacy of the Anti-CD22 Recombinant Immunotoxin BL22 in Chemotherapy-Resistant Hairy-Cell Leukemia

✍ Scribed by Kreitman, Robert J.; Wilson, Wyndham H.; Bergeron, Karen; Raggio, Miranda; Stetler-Stevenson, Maryalice; FitzGerald, David J.; Pastan, Ira

Book ID: 120037947
Publisher: Massachusetts Medical Society
Year: 2001
Tongue: English
Weight: 151 KB
Volume: 345
Category: Article
ISSN: 0096-6762
DOI: 10.1056/NEJM200107263450402

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I Trial of Anti-CD22 Recombinant I

Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia

✍ Kreitman, R. J.; Tallman, M. S.; Robak, T.; Coutre, S.; Wilson, W. H.; Stetler-S 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 184 KB

Characterization of T-cell repertoire in

Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy

✍ Evgeny Arons; Lynn Sorbara; Mark Raffeld; Maryalice Stetler-Stevenson; Seth M. S 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 499 KB

In vivo efficacy of the recombinant anti

In vivo efficacy of the recombinant anti-CD64 immunotoxin H22(scFv)-ETA′ in a human acute myeloid leukemia xenograft tumor model

✍ Mehmet Kemal Tur; Michael Huhn; Edgar Jost; Theo Thepen; Tim H. Brümmendorf; Ste 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 533 KB

## Abstract Target‐specific acute myeloid leukemia (AML) immunotherapy requires selective cell‐surface antigens on AML blast cells. CD64 is a promising candidate antigen because it is abundantly expressed on monocytoid differentiated AML subtypes. In previous studies, a chemically linked full‐lengt

Anti-CD19 and anti-CD22 monoclonal antib

Anti-CD19 and anti-CD22 monoclonal antibodies increase the effectiveness of chemotherapy in Pre-B acute lymphoblastic leukemia cell lines

✍ C. Stanciu-Herrera; C. Morgan; L. Herrera 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 691 KB

Evaluation of four CD22 antibodies as ri

Evaluation of four CD22 antibodies as ricin a chain-containing immunotoxins for the in vivo therapy of human B-cell leukemias and lymphomas

✍ Guo-Liang Shen; Jia-Ling Li; Maria-Ana Ghetie; Victor Ghetie; Richard D. May; Ma 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 French ⚖ 668 KB

Ricin A chain-containing immunotoxins (IT-As) specific for the human &ell antigen, CD22, were prepared from 4 monoclonal antibodies (MAbs) or their Fab' fragments: RFB4, HD6, UV22-I and UV22-2. The ITS were tested for their ability to kill cells from the Burkitt lymphoma line, Daudi, the pre-6cell l

Complete regression of human B-cell lymp

Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys

✍ Robert J. Kreitman,; Qing-Cheng Wang,; David J.P. FitzGerald; Ira Pastan 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 French ⚖ 161 KB

RFB4(dsFv)-PE38 is a recombinant immunotoxin in which the variable light domain (V L ) is disulfide bonded via cysteine residues to the variable heavy domain (V H ), which in turn is fused to PE38, a mutant form of Pseudomonas exotoxin A. RFB4 binds to CD22, which is a differentiation antigen expres